Cellectis S.A. (CLLS) vs Korro Bio (KRRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cellectis S.A. (CLLS) has outperformed Korro Bio (KRRO) over the past year, losing 64.9% versus a loss of 78.5%. Over five years, CLLS leads with a -87.6% price change compared with -97.0% for KRRO. Korro Bio is the larger company by market cap ($155.8 million vs $125.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | KRRO |
|---|---|---|
| Share price | $1.25 | $10.58 |
| Market cap | $125.90M | $155.80M |
| 1-day change | -6.72% | +0.86% |
| YTD return | -72.31% | +30.96% |
| 1-year return | -64.92% | -78.49% |
| 5-year return | -87.63% | -97.05% |
| EPS (TTM) | $-0.64 | $-9.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $55.89 |
| 52-week low | $1.22 | $5.20 |
| Distance from 52-week high | -77.19% | -81.07% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +326.40% | +90.93% |
| Average volume | 78.59K | 148.80K |
| Shares outstanding | 72.72M | 14.73M |
| Employees | 224 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLLS has outperformed KRRO by 13.6 percentage points over the past year.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
CLLS vs KRRO FAQ
Which is bigger, Cellectis S.A. or Korro Bio?
Korro Bio (KRRO) is larger, with a market capitalization of $155.80M compared with $125.90M for Cellectis S.A. (CLLS).
Which stock has performed better over the past year, CLLS or KRRO?
CLLS returned -64.92% over the past 12 months, compared with -78.49% for KRRO (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Korro Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.